Top

Journal of Clinical Immunology

Published in:

01-01-2019 | Original Article

Lymphocyte Apoptosis and FAS Expression in Patients with 22q11.2 Deletion Syndrome

Authors: Dina M. Aresvik, Torstein Øverland, Kari Lima, Rolf D. Pettersen, Tore G. Abrahamsen

Published in: Journal of Clinical Immunology | Issue 1/2019

Abstract

Purpose

Immunodeficiency is one of the key features of 22q11.2 deletion syndrome (del), and it is seen in approximately 75% of the patients. The degree of immunodeficiency varies widely, from no circulating T cells to normal T cell counts. It has been hypothesized that the low number of T cells may at least in part be due to increased apoptosis of T cells. Increased spontaneous T cell apoptosis has been reported in one patient with 22q11.2del, but this has not been further investigated.

Methods

A national cohort of patients with a proven heterozygous deletion of chromosome 22q11.2 diagnosed by FISH or MLPA and a group of age and sex matched controls were studied. Spontaneous and activation-induced apoptosis, in addition to FAS expression on lymphocytes, were measured using flow cytometry. Serum levels of FASL were analyzed using ELISA.

Results

There was no increased spontaneous apoptosis in patients with 22q11.2del. Upon activation, anti-FAS-induced apoptosis was significantly increased in patients compared to those in controls, while there was no difference in activation induced cell death or activated cell autonomous death. We also found a significant increase in expression of FAS on freshly isolated lymphocytes from patients, while there was no difference in serum levels of FASL. Patients with congenital heart defects (CHD) had significantly higher serum levels of FASL compared to non-CHD patients.

Conclusion

We have shown increased FAS expression on lymphocytes from patients with 22q11.2del as well as increased levels of FASL in patients with CHD. Those changes may contribute to the pathophysiology of the 22q11.2del.

Available only for authorised users

McDonald-McGinn DM, Sullivan KE, Marino B, Philip N, Swillen A, Vorstman JA, et al. 22q11.2 deletion syndrome. Nat Rev Dis Primers. 2015;1:15071. https://doi.org/10.1038/nrdp.2015.71.CrossRefPubMedPubMedCentral

Oskarsdottir S, Vujic M, Fasth A. Incidence and prevalence of the 22q11 deletion syndrome: a population-based study in Western Sweden. Arch Dis Child. 2004;89(2):148–51.CrossRefPubMedPubMedCentral

Lima K, Folling I, Eiklid KL, Natvig S, Abrahamsen TG. Age-dependent clinical problems in a Norwegian national survey of patients with the 22q11.2 deletion syndrome. Eur J Pediatr. 2010;169(8):983–9. https://doi.org/10.1007/s00431-010-1161-3.CrossRefPubMed

McDonald-McGinn DM, Sullivan KE. Chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Medicine (Baltimore). 2011;90(1):1–18. https://doi.org/10.1097/MD.0b013e3182060469.CrossRef

Crowley B, Ruffner M, McDonald McGinn DM, Sullivan KE. Variable immune deficiency related to deletion size in chromosome 22q11.2 deletion syndrome. Am J Med Genet A. 2018. https://doi.org/10.1002/ajmg.a.38597.

Sullivan KE. Chromosome 22q11.2 deletion syndrome: DiGeorge syndrome/velocardiofacial syndrome. Immunol Allergy Clin N Am. 2008;28(2):353–66. https://doi.org/10.1016/j.iac.2008.01.003.CrossRef

Jawad AF, McDonald-Mcginn DM, Zackai E, Sullivan KE. Immunologic features of chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). J Pediatr. 2001;139(5):715–23. https://doi.org/10.1067/mpd.2001.118534.CrossRefPubMed

Gennery AR. Immunological features of 22q11 deletion syndrome. Curr Opin Pediatr. 2013;25(6):730–5. https://doi.org/10.1097/MOP.0000000000000027.CrossRefPubMed

Gupta S, Aggarwal S, Nguyen T. Increased spontaneous apoptosis in T lymphocytes in DiGeorge anomaly. Clin Exp Immunol. 1998;113(1):65–71.CrossRefPubMedPubMedCentral

10.

Pierdominici M, Marziali M, Giovannetti A, Oliva A, Rosso R, Marino B, et al. T cell receptor repertoire and function in patients with DiGeorge syndrome and velocardiofacial syndrome. Clin Exp Immunol. 2000;121(1):127–32.CrossRefPubMedPubMedCentral

11.

Zhou H, Perkins SL, Tripp S, Hussong JW, Coffin CM. Expression of apoptosis-related antigens, Fas, bcl-2, and p53, and Mib-1 proliferation index in the hypoplastic thymus of DiGeorge syndrome. Pediatr Dev Pathol. 2002;5(5):465–71. https://doi.org/10.1007/s10024-002-2004-7.CrossRefPubMed

12.

Krueger A, Fas SC, Baumann S, Krammer PH. The role of CD95 in the regulation of peripheral T-cell apoptosis. Immunol Rev. 2003;193:58–69.CrossRefPubMed

13.

Brenner D, Krammer PH, Arnold R. Concepts of activated T cell death. Crit Rev Oncol Hematol. 2008;66(1):52–64. https://doi.org/10.1016/j.critrevonc.2008.01.002.CrossRefPubMed

14.

Zhang N, Hartig H, Dzhagalov I, Draper D, He YW. The role of apoptosis in the development and function of T lymphocytes. Cell Res. 2005;15(10):749–69. https://doi.org/10.1038/sj.cr.7290345.CrossRefPubMed

15.

de la Fuente MA, Recher M, Rider NL, Strauss KA, Morton DH, Adair M, et al. Reduced thymic output, cell cycle abnormalities, and increased apoptosis of T lymphocytes in patients with cartilage-hair hypoplasia. J Allergy Clin Immunol. 2011;128(1):139–46. https://doi.org/10.1016/j.jaci.2011.03.042.CrossRefPubMedPubMedCentral

16.

Yazdani R, Fatholahi M, Ganjalikhani-Hakemi M, Abolhassani H, Azizi G, Hamid KM, et al. Role of apoptosis in common variable immunodeficiency and selective immunoglobulin A deficiency. Mol Immunol. 2016;71:1–9. https://doi.org/10.1016/j.molimm.2015.12.016.CrossRefPubMed

17.

Rieux-Laucat F, Magerus-Chatinet A, Neven B. The autoimmune lymphoproliferative syndrome with defective FAS or FAS-ligand functions. J Clin Immunol. 2018;38:558–68. https://doi.org/10.1007/s10875-018-0523-x.CrossRefPubMed

18.

Gupta S. Molecular mechanisms of apoptosis in the cells of the immune system in human aging. Immunol Rev. 2005;205:114–29. https://doi.org/10.1111/j.0105-2896.2005.00261.x.CrossRefPubMed

19.

Lecoeur H, Ledru E, Prevost MC, Gougeon ML. Strategies for phenotyping apoptotic peripheral human lymphocytes comparing ISNT, annexin-V and 7-AAD cytofluorometric staining methods. J Immunol Methods. 1997;209(2):111–23.CrossRefPubMed

20.

Zou KH, Tuncali K, Silverman SG. Correlation and simple linear regression. Radiology. 2003;227(3):617–22. https://doi.org/10.1148/radiol.2273011499.CrossRefPubMed

21.

Krammer PH, Arnold R, Lavrik IN. Life and death in peripheral T cells. Nat Rev Immunol. 2007;7(7):532–42. https://doi.org/10.1038/nri2115.CrossRefPubMed

22.

Strasser A, Jost PJ, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity. 2009;30(2):180–92. https://doi.org/10.1016/j.immuni.2009.01.001.CrossRefPubMedPubMedCentral

23.

Li X, Zhang Z, Peng A, He M, Xu J, Shen S, et al. Effect of CD95 on inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes. Cell Immunol. 2014;290(2):209–16. https://doi.org/10.1016/j.cellimm.2014.07.004.CrossRefPubMed

24.

Klebanoff CA, Scott CD, Leonardi AJ, Yamamoto TN, Cruz AC, Ouyang C, et al. Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy. J Clin Invest. 2016;126(1):318–34. https://doi.org/10.1172/JCI81217.CrossRefPubMed

25.

Arai K, Liu ZX, Lane T, Dennert G. IP-10 and Mig facilitate accumulation of T cells in the virus-infected liver. Cell Immunol. 2002;219(1):48–56.CrossRefPubMed

26.

Choi K, Ni L, Jonakait GM. Fas ligation and tumor necrosis factor alpha activation of murine astrocytes promote heat shock factor-1 activation and heat shock protein expression leading to chemokine induction and cell survival. J Neurochem. 2011;116(3):438–48. https://doi.org/10.1111/j.1471-4159.2010.07124.x.CrossRefPubMed

27.

Aresvik DM, Lima K, Overland T, Mollnes TE, Abrahamsen TG. Increased levels of interferon-inducible protein 10 (IP-10) in 22q11.2 deletion syndrome. Scand J Immunol. 2016;83(3):188–94. https://doi.org/10.1111/sji.12406.CrossRefPubMed

28.

Toyozaki T, Hiroe M, Tanaka M, Nagata S, Ohwada H, Marumo F. Levels of soluble Fas ligand in myocarditis. Am J Cardiol. 1998;82(2):246–8.CrossRefPubMed

29.

Yamaguchi S, Yamaoka M, Okuyama M, Nitoube J, Fukui A, Shirakabe M, et al. Elevated circulating levels and cardiac secretion of soluble Fas ligand in patients with congestive heart failure. Am J Cardiol. 1999;83(10):1500–3 A8.CrossRefPubMed

30.

Shimizu M, Fukuo K, Nagata S, Suhara T, Okuro M, Fujii K, et al. Increased plasma levels of the soluble form of Fas ligand in patients with acute myocardial infarction and unstable angina pectoris. J Am Coll Cardiol. 2002;39(4):585–90.CrossRefPubMed

31.

Huby AC, Turdi S, James J, Towbin JA, Purevjav E. FasL expression in cardiomyocytes activates the ERK1/2 pathway, leading to dilated cardiomyopathy and advanced heart failure. Clin Sci (Lond). 2016;130(4):289–99. https://doi.org/10.1042/CS20150624.CrossRef

32.

Sahinarslan A, Boyaci B, Kocaman SA, Topal S, Ercin U, Okyay K, et al. The relationship of serum soluble Fas ligand (sFasL) level with the extent of coronary artery disease. Int J Angiol. 2012;21(1):29–34. https://doi.org/10.1055/s-0032-1306418.CrossRefPubMedPubMedCentral

33.

Miyoshi T, Hosoda H, Nakai M, Nishimura K, Miyazato M, Kangawa K, et al. Maternal biomarkers for fetal heart failure in fetuses with congenital heart defects or arrhythmias. Am J Obstet Gynecol. 2018. https://doi.org/10.1016/j.ajog.2018.09.024.

34.

Sallee D, Qiu Y, Liu J, Watanabe M, Fisher SA. Fas ligand gene transfer to the embryonic heart induces programmed cell death and outflow tract defects. Dev Biol. 2004;267(2):309–19. https://doi.org/10.1016/j.ydbio.2003.11.020.CrossRefPubMed

Title: Lymphocyte Apoptosis and FAS Expression in Patients with 22q11.2 Deletion Syndrome
Authors: Dina M. Aresvik
Torstein Øverland
Kari Lima
Rolf D. Pettersen
Tore G. Abrahamsen
Publication date: 01-01-2019
Publisher: Springer US
Published in: Journal of Clinical Immunology / Issue 1/2019
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-018-0579-7

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Lymphocyte Apoptosis and FAS Expression in Patients with 22q11.2 Deletion Syndrome

Abstract

Purpose

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2019

A Novel STK4 Mutation Presenting with Juvenile Idiopathic Arthritis and Epidermodysplasia Verruciformis

Progressive Multifocal Leukoencephalopathy in Primary Immunodeficiencies

Two Prenatal Cases of Hyper-IgE Syndrome

Outcomes for Nitazoxanide Treatment in a Case Series of Patients with Primary Immunodeficiencies and Rubella Virus-Associated Granuloma

MonoMAC Syndrome Caused by a Novel GATA2 Mutation Successfully Treated by Allogeneic Hematopoietic Stem Cell Transplantation

DDX58 and Classic Singleton-Merten Syndrome

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page